Marc Spentchian

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 409 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

Stéphane Prost, Francis Relouzat, Marc Spentchian et al. · Nature · 2015 · 258 citations · Full text

Medicine, Cell Biology, Pharmacology +12

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

Philippe Rousselot, Clémence Loiseau, Marc Delord et al. · Blood Advances · 2020 · 59 citations · Full text

Medicine, Hematology, Oncology +13

Time course of troponin I, myoglobin, and cardiac enzyme release after electrical cardioversion

Jean‐Louis Georges, Marc Spentchian, Christine Caubel et al. · The American Journal of Cardiology · 1996 · 46 citations

Medicine, Cardiology, Physiology +15

Evidence of a founder effect for the tissue-nonspecific alkaline phosphatase (TNSALP) gene E174K mutation in hypophosphatasia patients

Muriel Hérasse, Marc Spentchian, A. Taillandier et al. · European Journal of Human Genetics · 2002 · 35 citations

Life Sciences, Genetics, Molecular Genetics +12